Methods and compositions for delivering peptides

ABSTRACT

Methods are provided for purifying peptides and proteins by incorporating the peptide or protein into a diketopiperazine or competitive complexing agent to facilitate removal one or more impurities, from the peptide or protein. Formulations and methods also are provided for the improved transport of active agents across biological membranes, resulting for example in a rapid increase in blood agent concentration. The formulations include microparticles formed of (i) the active agent, which may be charged or neutral, and (ii) a transport enhancer that masks the charge of the agent and/or that forms hydrogen bonds with the target biological membrane in order to facilitate transport. In one embodiment, insulin is administered via the pulmonary delivery of microparticles comprising fumaryl diketopiperazine and insulin in its biologically active form. This method of delivering insulin results in a rapid increase in blood insulin concentration that is comparable to the increase resulting from intravenous delivery.

CROSS-REFERENCE TO RELATED APPLICATIONS

This application is a continuation of U.S. patent application Ser. No.10/719,734 filed Nov. 21, 2003, which is a continuation of U.S. patentapplication Ser. No. 10/224,761 filed Aug. 20, 2002, now U.S. Pat. No.6,652,885 which is a division of U.S. patent application Ser. No.09/606,468 filed Jun. 29, 2000, now U.S. Pat. No. 6,444,226 which interm claims the benefit under 37 CFR §119(e) to provisional patentapplication No. 60/141,433 filed Jun. 29, 1999. Each of theseapplications and patents are incorporated by reference herein in theirentirety.

BACKGROUND OF THE INVENTION

The present invention is generally in the field of pharmaceuticalformulations, and more particularly related to methods and compositionsfor purifying and stabilizing peptides and proteins, such as insulin,which are used in pharmaceutical applications.

In a normal person, the β-cells of the pancreatic islets of Langerhansproduce insulin, required by the body for glucose metabolism, inresponse to an increase in blood glucose concentration. The insulinmetabolizes incoming glucose and temporarily stops the liver'sconversion of glycogen and lipids to glucose thereby allowing the bodyto support metabolic activity between meals. The Type I diabetic,however, has a reduced ability or absolute inability to produce insulindue to β-cell destruction and needs to replace the insulin via dailyinjections or an insulin pump. More common than Type I diabetes, though,is Type II diabetes, which is characterized by insulin resistance andincreasingly impaired pancreatic β-cell function. Type II diabetics maystill produce insulin, but they may also require insulin replacementtherapy.

Type II diabetics typically exhibit a delayed response to increases inblood glucose levels. While normal persons usually release insulinwithin 2-3 minutes following the consumption of food, Type II diabeticsmay not secrete endogenous insulin for several hours after consumption.As a result, endogenous glucose production continues after consumption(Pfeiffer, Am. J. Med., 70:579-88 (1981)), and the patient experienceshyperglycemia due to elevated blood glucose levels.

Loss of glucose-induced insulin secretion is one of the earliestdisturbances of β-cell function (Cerasi et al., Diabetes, 21:224-34(1972); Polonsky et al., N. Engl. J. Med., 318:1231-39 (1988)), but thecauses and degree of 6-cell dysfunction are unknown in most cases. Whilegenetic factors play an important role, (Leahy, Curr. Opin. Endocrinol.Diabetes, 2:300-06 (1995)), some insulin secretory disturbances seem tobe acquired and may be at least partially reversible through optimalglucose control. Optimal glucose control via insulin therapy after ameal can lead to a significant improvement in natural glucose-inducedinsulin release by requiring both normal tissue responsiveness toadministered insulin and an abrupt increase in serum insulinconcentrations. Therefore, the challenge presented in the treatment ofearly stage Type II diabetics, those who do not have excessive loss ofβ-cell function, is to restore the release of insulin following meals.

Most early stage Type II diabetics currently are treated with oralagents, but with little success. Subcutaneous injections of insulin arealso rarely effective in providing insulin to Type II diabetics and mayactually worsen insulin action because of delayed, variable, and shallowonset of action. It has been shown, however, that if insulin isadministered intravenously with a meal, early stage Type II diabeticsexperience the shutdown of hepatic glucogenesis and exhibit increasedphysiological glucose control. In addition, their free fatty acidslevels fall at a faster rate than without insulin therapy. Whilepossibly effective in treating Type II diabetes, intravenousadministration of insulin, is not a reasonable solution, as it is notsafe or feasible for patients to intravenously administer insulin atevery meal.

Insulin, a polypeptide with a nominal molecular weight of 6,000 Daltons,traditionally has been produced by processing pig and cow pancreas toisolate the natural product. More recently, however, recombinanttechnology has been used to produce human insulin in vitro. Natural andrecombinant human insulin in aqueous solution is in a hexamericconfiguration, that is, six molecules of recombinant insulin arenoncovalently associated in a hexameric complex when dissolved in waterin the presence of zinc ions. Hexameric insulin is not rapidly absorbed.In order for recombinant human insulin to be absorbed into a patient'scirculation, the hexameric form must first dissociate into dimericand/or monomeric forms before the material can move into the bloodstream. The delay in absorption requires that the recombinant humaninsulin be administered approximately one half hour prior to meal timein order to produce therapeutic insulin blood level, which can beburdensome to patients who are required to accurately anticipate thetimes they will be eating. To overcome this delay, analogs ofrecombinant human insulin, such as HUMALOG™, have been developed, whichrapidly disassociate into a virtually entirely monomeric form followingsubcutaneous administration. Clinical studies have demonstrated thatHUMALOG™ is absorbed quantitatively faster than recombinant humaninsulin after subcutaneous administration. See, for example, U.S. Pat.No. 5,547,929 to Anderson Jr., et al.

In a effort to avoid the disadvantages associated with delivery byinjection and to speed absorption, administration of monomeric analogsof insulin via the pulmonary route has been developed. For example, U.S.Pat. No. 5,888,477 to Gonda, et al. discloses having a patient inhale anaerosolized formulation of monomeric insulin to deposit particles ofinsulin on the patient's lung tissue. However, the monomeric formulationis unstable and rapidly loses activity, while the rate of uptake remainsunaltered.

While it would be desirable to produce rapidly absorbable insulinderived from natural sources, transformation of the hexameric form intothe monomeric form, such as by removing the zinc from the complex,yields an insulin that is unstable and has an undesirably short shelflife. It therefore would be desirable to provide monomeric forms ofinsulin, while maintaining its stability in the absence of zinc. It alsowould be advantageous to provide diabetic patients with monomericinsulin compositions that are suitable for pulmonary administration,provide rapid absorption, and which can be produced in ready-to-useformulations that have a commercially useful shelf-life.

These problems with impurities, metal ions that affect stability orbioavailability, occur with many other proteins and peptides.

U.S. Pat. No. 6,071,497 to Steiner, et al. discloses microparticle drugdelivery systems in which the drug is encapsulated in diketopiperazinemicroparticles which are stable at a pH of 6.4 or less and unstable atpH of greater than 6.4, or which are stable at both acidic and basic pH,but which are unstable at pH between about 6.4 and 8. The patent doesnot describe monomeric insulin compositions that are suitable forpulmonary administration, provide rapid absorption, and which can beproduced in ready-to-use formulations that have a commercially usefulshelf-life.

It would therefore be advantageous to develop alternative insulindelivery compositions for Type II diabetics that provide more rapidelevation of insulin blood levels and are easily administered to ensurepatient compliance. It also would be desirable to apply the deliverycompositions and methods to other biologically active agents.

It is therefore an object of the present invention to provide improvedmethods for purifying peptides and proteins, especially in thepreparation of compositions suitable for pulmonary administration.

It is another object of the present invention to provide stablemonomeric peptide compositions suitable for pulmonary delivery.

It is a further object of the present invention to provide methods andcompositions for the facilitated transport of insulin and otherbiologically active agents across biological membranes.

It is another object of the present invention to provide methods andcompositions for the improved absorption of insulin or otherbiologically active agents in the bloodstream.

It is a still further object of the present invention to provide methodsand compositions for the improved absorption of insulin or otherbiologically active agents in the bloodstream characterized by ease ofadministration.

SUMMARY OF THE INVENTION

Methods are provided for purifying peptides and proteins byincorporating the peptide or protein into a diketopiperazine orcompetitive complexing agent to facilitate removal one or moreimpurities, i.e. undesirable components, from the peptide or protein. Ina preferred embodiment, a peptide, such as insulin, containing one ormore impurities, e.g., zinc ions, is entrapped in diketopiperazine toform a precipitate of peptide/diketopiperazine/impurity, which is thenwashed with a solvent for the impurity to be removed, which is anonsolvent for the diketopiperazine and a nonsolvent for the peptide.Alternatively, the impurity can be removed by using complexing agents toselectively complex with and displace the impurities, for example, suchas by dialysis.

Formulations and methods also are provided for the improved transport ofactive agents across biological membranes, resulting, for example, in arapid increase in blood agent concentration. The formulations includemicroparticles formed of (i) the active agent, which may be charged orneutral, and (ii) a transport enhancer that masks the charge of theagent and/or that forms hydrogen bonds with the target biologicalmembrane in order to facilitate transport. In a preferred embodiment,insulin is administered via pulmonary delivery of microparticlescomprising fumaryl diketopiperazine and insulin in its biologicallyactive form. The charge on the insulin molecule is masked by hydrogenbonding it to the diketopiperazine, thereby enabling the insulin to passthrough the target membrane. This method of delivering insulin resultsin a rapid increase in blood insulin concentration that is comparable tothe increase resulting from intravenous delivery.

BRIEF DESCRIPTION OF THE DRAWINGS

FIG. 1 a is a graph of mean blood glucose values over time (minutes).

FIG. 1 b is a graph of mean C-peptide concentrations during experimentscomparing levels of C-peptide (ng/ml) over time (minutes) when insulinwas administered intravenously, subcutaneously, and by inhalation.

FIG. 2 a is a graph of glucose infusion rate (mg/kg/min) over time(minutes) comparing insulin administered intravenously, subcutaneously,and by inhalation.

FIG. 2 b is a graph of mean insulin concentrations (μU/ml) over time(minutes) comparing insulin administered intravenously, subcutaneously,and by inhalation.

DETAILED DESCRIPTION OF THE INVENTION

Encapsulation or entrapment of large polymers, such as proteins andpeptides, in diketopiperazines can be used to remove impurities orcontaminants such as metal ions or other small molecules. Thediketopiperazines also serve both to stabilize and enhance delivery ofthe entrapped materials. Formulations also have been developed for theenhanced transport of active agents across biological membranes. Theseformulations include microparticles formed of (i) the active agent,which may be charged or neutral, and (ii) a transport enhancer thatmasks the charge of the agent and/or that forms hydrogen bonds with themembrane. The formulations can provide rapid increases in theconcentration of active agent in the blood following administration ofthe formulations.

For example, it was discovered that hexameric insulin can be deliveredto the lung in fumaryl diketopiperazine formulation, reaching peak bloodconcentrations within 3-10 minutes. In contrast, insulin administered bythe pulmonary route without fumaryl diketopiperazine typically takesbetween 25-60 minutes to reach peak blood concentrations, whilehexameric insulin takes 30-90 minutes to reach peak blood level whenadministered by subcutaneous injection. This feat has been successfullyreplicated several times and in several species, including humans.

Removing zinc from insulin typically produces unstable insulin with anundesirably short shelf life. Purification to remove zinc, stabilizationand enhanced delivery of insulin is demonstrated by the examples.Formulations of insulin trapped in fumaryl diketopiperazine were foundto be stable and have an acceptable shelf life. Measurement of the zinclevels demonstrated that the zinc had been largely removed during theentrapment process, yielding monomeric insulin in a stable deliveryformulation.

Rapid absorption of a number of other peptides, including salmoncalcitonin, parathyroid hormone 1-34, octreotide, leuprolide and RSVpeptide, has been observed when the peptide is pulmonarily delivered infumaryl diketopiperazine—providing peak blood concentrations within 3-10minutes after pulmonary delivery.

Materials

A. Agent to be Delivered

The agent to be delivered is referred to herein as the active agent, ormolecule to be encapsulated or entrapped. It may or may not be a chargedspecies. Examples of classes of active agents suitable for use in thecompositions and methods described herein include therapeutic,prophylactic, and diagnostic agents, as well as dietary supplements,such as vitamins.

The exact mechanism by which the diketopiperazines form a complex withthe materials to be delivered is not known, but it is believed that thediketopiperazines form a complex with the material to be purified. Thisprocess is referred to herein interchangeably as entrapment orencapsulation.

These materials can be any polymer or large organic molecules, mostpreferably peptides and proteins. Generally speaking, any form of drugcan be entrapped. Examples include synthetic inorganic and organiccompounds, proteins and peptides, polysaccharides and other sugars,lipids, and nucleic acid sequences having therapeutic, prophylactic ordiagnostic activities. Proteins are defined as consisting of 100 aminoacid residues or more; peptide are less than 100 amino acid residues.Unless otherwise stated, the term protein refers to both proteins andpeptides. The agents to be incorporated can have a variety of biologicalactivities, such as vasoactive agents, neuroactive agents, hormones,anticoagulants, immunomodulating agents, cytotoxic agents, antibiotics,antivirals, antisense, antigens, and antibodies. In some instances, theproteins may be antibodies or antigens which otherwise would have to beadministered by injection to elicit an appropriate response.Representative polymers including proteins, peptides, polysaccharides,nucleic acid molecule, and combinations thereof.

Preferred peptides and proteins include hormones, cytokines and otherimmunomodulatory peptides, and antigens/vaccines. In a preferredembodiment, the active agent is monomeric insulin or a stabilized formof insulin which has been purified to remove zinc. In another preferredembodiment, the active agent is glucagon.

The active agent, or drug, can be an antigen, where the molecule isintended to elicit a protective immune response, especially against anagent that preferentially infects the lungs, such as mycoplasma,bacteria causing pneumonia, and respiratory synticial virus. In thesecases, it may also be useful to administer the drug in combination withan adjuvant, to increase the immune response to the antigen.

Any genes that would be useful in replacing or supplementing a desiredfunction, or achieving a desired effect such as the inhibition of tumorgrowth, could be introduced using the matrices described herein. As usedherein, a “gene” is an isolated nucleic acid molecule of greater thanthirty nucleotides, preferably one hundred nucleotides or more, inlength. Examples of genes which replace or supplement function includethe genes encoding missing enzymes such as adenosine deaminase (ADA)which has been used in clinical trials to treat ADA deficiency andcofactors such as insulin and coagulation factor VIII. Genes whicheffect regulation can also be administered, alone or in combination witha gene supplementing or replacing a specific function. For example, agene encoding a protein which suppresses expression of a particularprotein-encoding gene, or vice versa, which induces expresses of aprotein-encoding gene, can be administered in the matrix. Examples ofgenes which are useful in stimulation of the immune response includeviral antigens and tumor antigens, as well as cytokines (tumor necrosisfactor) and inducers of cytokines (endotoxin), and variouspharmacological agents.

Other nucleic acid sequences that can be utilized include antisensemolecules which bind to complementary DNA to inhibit transcription,ribozyme molecules, and external guide sequences used to target cleavageby RNAase P.

As used herein, vectors are agents that transport the gene into targetedcells and include a promoter yielding expression of the gene in thecells into which it is delivered. Promoters can be general promoters,yielding expression in a variety of mammalian cells, or cell specific,or even nuclear versus cytoplasmic specific. These are known to thoseskilled in the art and can be constructed using standard molecularbiology protocols. Vectors increasing penetration, such as lipids,liposomes, lipid conjugate forming molecules, surfactants, and othermembrane permeability enhancing agents are commercially available andcan be delivered with the nucleic acid.

Imaging agents including metals, radioactive isotopes, radioopaqueagents, fluorescent dyes, and radiolucent agents also can beincorporated. Examples of radioisotopes and radioopaque agents includegallium, technetium, indium, strontium, iodine, barium, and phosphorus.

Impurities which can be removed from the active agent compositioninclude metal ions such as zinc, and other di- or multi-valent ions, andsmall inorganic molecules and solvent residuals.

B. Diketopiperazines

Diketopiperazines useful in the present compositions and methods aredescribed, for example, in U.S. Pat. No. 6,071,497, which isincorporated herein in its entirety.

(i). General Formula

The diketopiperazines or their substitution analogs are rigid planarrings with at least six ring atoms containing heteroatoms and unbondedelectron pairs. One or both of the nitrogens can be replaced with oxygento create the substitution analogs diketomorpholine and diketodioxane,respectively. Although it is possible to replace a nitrogen with asulfur atom, this does not yield a stable structure.

The general formulae for diketopiperazine and its analogs are shownbelow.

Wherein n is between 0 and 7, Q is, independently, a C₁₋₂₀ straight,branched or cyclic alkyl, aralkyl, alkaryl, alkenyl, alkynyl,heteroalkyl, heterocyclic, alkyl-heterocyclic, or heterocyclic-alkyl; Tis —C(O)O, —OC(O), —C(O)NH, —NH, —NQ, —OQO, —O, —NHC(O), —OP(O), —P(O)O,—OP(O)₂, —P(O)₂O, —OS(O)₂, or —S(O)₃; U is an acid group, such as acarboxylic acid, phosphoric acid, phosphonic acid and sulfonic acid, ora basic group, such as primary, secondary and tertiary amines,quaternary ammonium salts, guanidine, aniline, heterocyclic derivatives,such as pyridine and morpholine, or a zwitterionic C₁₋₂₀ chaincontaining at least one acidic group and at least one basic group, forexample, those described above, wherein the side chains can be furtherfunctionalized with an alkene or alkyne group at any position, one ormore of the carbons on the side chain can be replaced with an oxygen,for example, to provide short polyethylene glycol chains, one or more ofthe carbons can be functionalized with an acidic or basic group, asdescribed above, and wherein the ring atoms X at positions 1 and 4 areeither O or N.

As used herein, “side chains” are defined as Q-T-Q-U or Q-U, wherein Q,T, and U are defined above.

Examples of acidic side chains include, but are not limited, to cis andtrans —CH═CH═CO₂H, —CH(CH₃)═CH(CH₃)—CO₂H, —(CH₂)₃—CO₂H,—CH₂CH(CH₃)—CO₂H, —CH(CH₂CO₂H)αCH₂, -(tetrafluoro)benzoic acid, -benzoicacid and —CH(NHC(O)CF₃)—CH₂—CO₂H.

Examples of basic side chains include, but are not limited to, -aniline,-phenyl-C(NH)NH₂, -phenyl-C(NH)NH(alkyl), -phenyl-C(NH)N(alkyl)₂ and—(CH₂)₄NHC(O)CH(NH₂)CH(NH₂)CO₂H.

Examples of zwitterionic side chains include, but are not limited to,—CH(NH₂)—CH₂—CO₂H and —NH(CH₂)₁₋₂₀CO₂H.

The term aralkyl refers to an aryl group with an alkyl substituent.

The term heterocyclic-alkyl refers to a heterocyclic group with an alkylsubstituent.

The term alkaryl refers to an alkyl group that has an aryl substituent.

The term alkyl-heterocyclic refers to an alkyl group that has aheterocyclic substituent.

The term alkene, as referred to herein, and unless otherwise specified,refers to an alkene group of C₂ to C₁₀, and specifically includes vinyland allyl.

The term alkyne, as referred to herein, and unless otherwise specified,refers to an alkyne group of C₂ to C₁₀. As used herein,“diketopiperazines” includes diketopiperazines and derivatives andmodifications thereof falling within the scope of the above-generalformula.

Fumaryl diketopiperazine is most preferred for pulmonary applications.

(ii). Synthesis

Diketopiperazines can be formed by cyclodimerization of amino acid esterderivatives, as described by Katchalski, et al., J. Amer. Chem. Soc.68:879-80 (1946), by cyclization of dipeptide ester derivatives, or bythermal dehydration of amino acid derivatives in high-boiling solvents,as described by Kopple, et al., J. Org. Chem. 32(2):862-64 (1968), theteachings of which are incorporated herein.2,5-diketo-3,6-di(aminobutyl)piperazine (Katchalski et al. refer to thisas lysine anhydride) was prepared via cyclodimerization ofN-epsilon-P-L-lysine in molten phenol, similar to the Kopple method inJ. Org. Chem., followed by removal of the blocking (P)-groups with 4.3 MHBr in acetic acid. This route is preferred because it uses acommercially available starting material, it involves reactionconditions that are reported to preserve stereochemistry of the startingmaterials in the product and all steps can be easily scaled up formanufacture.

Diketomorpholine and diketooxetane derivatives can be prepared bystepwise cyclization in a manner similar to that disclosed inKatchalski, et al., J. Amer. Chem. Soc. 68:879-80 (1946).

Diketopiperazines can be radiolabelled. Means for attaching radiolabelsare known to those skilled in the art. Radiolabelled diketopiperazinescan be prepared, for example, by reacting tritium gas with thosecompounds listed above that contain a double or triple bond. A carbon-14radiolabelled carbon can be incorporated into the side chain by using¹⁴C labeled precursors which are readily available. These radiolabelleddiketopiperazines can be detected in vivo after the resultingmicroparticles are administered to a subject.

(a) Synthesis of Symmetrical

Diketopiperazine Derivatives

The diketopiperazine derivatives are symmetrical when both side chainsare identical. The side chains can contain acidic groups, basic groups,or combinations thereof.

One example of a symmetrical diketopiperazine derivative is2,5-diketo-3,6-di(4-succinylaminobutyl)piperazine.2,5-diketo-3,6-di(aminobutyl) piperazine is exhaustively succinylatedwith succinic anhydride in mildly alkaline aqueous solution to yield aproduct which is readily soluble in weakly alkaline aqueous solution,but which is quite insoluble in acidic aqueous solutions. Whenconcentrated solutions of the compound in weakly alkaline media arerapidly acidified under appropriate conditions, the material separatesfrom the solution as microparticles.

Other preferred compounds can be obtained by replacing the succinylgroup(s) in the above compound with glutaryl, maleyl or fumaryl groups.

(b) Synthesis of Asymmetrical

Diketopiperazine Derivatives

One method for preparing unsymmetrical diketopiperazine derivatives isto protect functional groups on the side chain, selectively deprotectone of the side chains, react the deprotected functional group to form afirst side chain, deprotect the second functional group, and react thedeprotected functional group to form a second side chain.

Diketopiperazine derivatives with protected acidic side chains, such ascyclo-Lys(P)Lys(P), wherein P is a benzyloxycarbonyl group, or otherprotecting group known to those skilled in the art, can be selectivelydeprotected. The protecting groups can be selectively cleaved by usinglimiting reagents, such as HBr in the case of the benzyloxycarbonylgroup, or fluoride ion in the case of silicon protecting groups, and byusing controlled time intervals. In this manner, reaction mixtures whichcontain unprotected, monoprotected and di-protected diketopiperazinederivatives can be obtained. These compounds have different solubilitiesin various solvents and pH ranges, and can be separated by selectiveprecipitation and removal. An appropriate solvent, for example, ether,can then be added to such reaction mixtures to precipitate all of thesematerials together. This can stop the deprotection reaction beforecompletion by removing the diketopiperazines from the reactants used todeprotect the protecting groups. By stirring the mixed precipitate withwater, both the partially and completely reacted species can bedissolved as salts in the aqueous medium. The unreacted startingmaterial can be removed by centrifugation or filtration. By adjustingthe pH of the aqueous solution to a weakly alkaline condition, theasymmetric monoprotected product containing a single protecting groupprecipitates from the solution, leaving the completely deprotectedmaterial in solution.

In the case of diketopiperazine derivatives with basic side chains, thebasic groups can also be selectively deprotected. As described above,the deprotection step can be stopped before completion, for example, byadding a suitable solvent to the reaction. By carefully adjusting thesolution pH, the deprotected derivative can be removed by filtration,leaving the partially and totally deprotected derivatives in solution.By adjusting the pH of the solution to a slightly acidic condition, themonoprotected derivative precipitates out of solution and can beisolated.

Zwitterionic diketopiperazine derivatives can also be selectivelydeprotected, as described above. In the last step, adjusting the pH to aslightly acidic condition precipitates the monoprotected compound with afree acidic group. Adjusting the pH to a slightly basic conditionprecipitates the monoprotected compound with a free basic group.

Limited removal of protecting groups by other mechanisms, including butnot limited to cleaving protecting groups that are cleaved byhydrogenation by using a limited amount of hydrogen gas in the presenceof palladium catalysts. The resulting product is also an asymmetricpartially deprotected diketopiperazine derivative. These derivatives canbe isolated essentially as described above.

The monoprotected diketopiperazine is reacted to produce adiketopiperazine with one sidechain and protecting group. Removal ofprotecting groups and coupling with other side chains yieldsunsymmetrically substituted diketopiperazines with a mix of acidic,basic, and zwitterionic sidechains.

Other materials that exhibit this response to pH can be obtained byfunctionalizing the amide ring nitrogens of the diketopiperazine ring.

C. Transport Enhancers

In a preferred embodiment, the active agent is complexed with atransport enhancer which is degradable and capable of forming hydrogenbonds with the target biological membrane in order to facilitatetransport of the agent across the membrane. The transport enhancer alsois capable of forming hydrogen bonds with the active agent, if charged,in order to mask the charge and facilitate transport of the agent acrossthe membrane. A preferred transport enhancer is diketopiperazine.

The transport enhancer preferably is biodegradable and may providelinear, pulsed or bulk release of the active agent. The transportenhancer may be a natural or synthetic polymer and may be modifiedthrough substitutions or additions of chemical groups, including alkyly,alkylene, hydroxylations, oxidations, and other modifications routinelymade by those skilled in the art.

A preferred transport enhancer is fumaryl diketopiperazine. Otherdiketopiperazines which may be useful as a transport enhancer aredescribed above.

Like most proteins and peptides, insulin is a charged molecule, whichimpedes its ability to cross charged biological membranes. It has beenfound that when insulin hydrogen bonds to fumaryl diketopiperazine, thecharge of the peptide is masked, thereby facilitating or enhancing thepassage of insulin across the membranes, such as mucosal membranes, andinto the blood.

II. Methods

A. Encapsulation

In one embodiment, active agent is encapsulated within microparticles bydissolving a diketopiperazine with acidic side chains in bicarbonate orother basic solution, adding the active agent in solution or suspension,and then precipitating the microparticle by adding acid, such as 1 Mcitric acid.

In another embodiment, active agent is encapsulated withinmicroparticles by dissolving a diketopiperazine with basic side chainsin an acidic solution, such as 1 M citric acid, adding the active agentin solution or suspension, and then precipitating the microparticle byadding bicarbonate or another basic solution.

In still another embodiment, active agent is encapsulated withinmicroparticles by dissolving a diketopiperazine with both acidic andbasic side chains in an acidic or basic solution, adding the activeagent in solution or suspension to be encapsulated, then precipitatingthe microparticle by neutralizing the solution.

The microparticles can be stored in the dried state and suspended foradministration to a patient. In the first embodiment, the reconstitutedmicroparticles maintain their stability in an acidic medium anddissociate as the medium approaches physiological pH in the range ofbetween 6 and 14. In the second embodiment, suspended microparticlesmaintain their stability in a basic medium and dissociate at a pH ofbetween 0 and 6. In the third embodiment, the reconstitutedmicroparticles maintain their stability in an acidic or basic medium anddissociate as the medium approaches physiological pH in the range of pHbetween 6 and 8.

The impurities typically are removed when the microparticles areprecipitated. However, impurities also can be removed by washing theparticles to dissolve the impurities. A preferred wash solution is wateror an aqueous buffer. Solvents other than water also can be used to washthe microspheres or precipitate the diketopiperazines, in order toremove impurities that are not water soluble. Any solvent in whichneither the cargo nor the fumaryl diketopiperazine is soluble aresuitable. Examples include acetic acid, ethanol, and toluene.

In an alternative embodiment, microparticles of diketopiperazine areprepared and provided in a suspension, typically an aqueous suspension,to which a solution of the active agent then is added. The suspension isthen lyophilized or freeze dried to yield diketopiperazinemicroparticles having a coating of active agent. In a preferredembodiment, the active agent is insulin in a hexameric form. Zinc ionscan then be removed by washing the microparticles with an appropriatesolvent.

As used herein, the term “entrapped” with reference to an active agentin/with a diketopiperazine includes coating of the active agent ontomicroparticles of the diketopiperazine.

The diketopiperazine microparticles have been found to have a higheraffinity for insulin than does zinc. Insulin has been found to bestabilized within an ordered lattice array of fumaryl diketopiperazine.In this state, in the sufficient absence of zinc ions, the insulin ispredominately dimeric and monomeric, as opposed to it hexameric state.The insulin therefore more readily dissociates to its monomeric state,which is the state in which insulin exerts its biological activity.

Other complexing agents may be substituted for the diketopiperazine.Other representative complexing agents include serum albumin and otherproteins, alginic acid, antibodies, cyclodextrins, phospholipids, andlecithin. For example, insulin contaminated with zinc can be complexedwith bovine serum albumin. The complex can be dialyzed in tubing with amolecular weight cut-off below 1,000 Daltons to separate and remove thezinc. Once sufficient amounts of zinc have been dialyzed away, asevidenced by its presence in the dialysate, the dispersion istransferred to dialysis tubing with a molecular weight cut-off below10,000 Daltons. Only monomeric insulin will pass through the tubing intothe dialysate, leaving any remaining hexameric zinc complexed insulinbehind. The purified insulin can be captured from the dialysate.

These materials may not, however, provide sufficient stabilization ofunstable or labile drugs.

B. Administration

The compositions of active agent described herein can be administered topatients in need of the active agent. The compositions preferably areadministered in the form of microparticles, which can be in a dry powderform for pulmonary administration or suspended in an appropriatepharmaceutical carrier, such as saline.

The microparticles preferably are stored in dry or lyophilized formuntil immediately before administration. The microparticles then can beadministered directly as a dry powder, such as by inhalation using, forexample, dry powder inhalers known in the art. Alternatively, themicroparticles can be suspended in a sufficient volume of pharmaceuticalcarrier, for example, as an aqueous solution for administration as anaerosol.

The microparticles also can be administered via oral, subcutaneous, andintravenous routes.

The compositions can be administered to any targeted biologicalmembrane, preferably a mucosal membrane of a patient. In a preferredembodiment, the patient is a human suffering from Type II diabetes. In apreferred embodiment, the composition delivers insulin in biologicallyactive form to the patient, which provides a spike of serum insulinconcentration which simulates the normal response to eating.

In a preferred embodiment, hexameric insulin is entrapped in fumaryldiketopiperazine to form a solid precipitate of monomeric insulin in thefumaryl diketopiperazine, which then is washed with aqueous solution toremove the free zinc. This formulation demonstrates blood uptakefollowing pulmonary administration at a rate 2.5 times the rate ofinsulin uptake following subcutaneous injection, with peak blood levelsoccurring at between 7.5 and 10 minutes after administration.

The range of loading of the drug to be delivered is typically betweenabout 0.01% and 90%, depending on the form and size of the drug to bedelivered and the target tissue. In a preferred embodiment usingdiketopiperazines, the preferred range is from 0.1% to 50% loading byweight of drug. The appropriate dosage can be determined, for example,by the amount of incorporated/encapsulated agent, the rate of itsrelease from the microparticles, and, in a preferred embodiment, thepatient's blood glucose level.

One preferred application is in the treatment of hyperinsulinemia. In apreferred embodiment, microparticles of the composition wherein theactive agent is glucagon can be administered by continuous subcutaneousinfusion. Glucagon is an extremely unstable peptide, but can bestabilized in particles of diketopiperazine, for example. The stabilizedglucagon/diketopiperazine microparticles can be made by adding glucagonto a solution of diketopiperazine which hydrogen bonds to the glucagonand when the solution is acidified, such as by adding a food acid, boththe diketopiperazine and the glucagon self-assemble to form uniformmicrospheres having a mean particle size of, for example, about 2 μm. Inthis process, approximately 95% of the glucagon is pulled out ofsolution and is evenly distributed within the diketopiperazinemicroparticle. These particles can readily be suspended and infusedsubcutaneously with a standard infusion pump. Then theglucagon/diketopiperazine particles are contacted with the near neutralpH environment of the subcutaneous fluid, where they dissolve, therebyreleasing glucagon in its pharmacologically active state.

The compositions and methods described herein are further described bythe following non-limiting examples.

Example 1 Removal of Zinc from U.S.P. Injectable Insulin

Insulin trapped in fumaryl diketopiperazine was analyzed to assesswhether zinc was removed during the entrapment process. The insulin usedas the starting material met U.S.P. standards for injectable insulin,and according to the certificate of analysis, the insulin contained aconsiderable quantity of zinc: 0.41%. This insulin was then entrapped infumaryl diketopiperazine to form a solid fumaryldiketopiperazine/insulin mixture, as described above.

Following entrapment of the insulin in fumaryl diketopiperazine, theamount of zinc theoretically should be present in the same proportion asit existed in the neat insulin. Using the certificate of analysis value,it was calculated that one should expect to find 697 parts per million(ppm) of zinc per gram in the solid yield of fumaryldiketopiperazine/insulin. Surprisingly, the quantity of zinc present thesolid fumaryl diketopiperazine/insulin was measured to be only 6 ppm.The “missing” zinc was presumably eliminated with the water used to washthe insulin/fumaryl diketopiperazine precipitate.

Example 2 Bioavailability of Insulin in Diketopiperazine PulmonaryFormulation

Subjects and Methods

The study was reviewed and approved by the ethical review committee ofthe Heinrich-Heine-University, Dusseldorf, and conducted according tolocal regulations, the Declaration of Helsinki and the rules of GoodClinical Practice.

The study was conducted with 5 healthy male volunteers. Inclusioncriteria were good health, as judged by physical examination, age: 18 to40 years, body mass index: 18 to 26 kg/m², capability to reach peakinspiratory flow of ≧4 l/sec measured by a computer assisted spirometryand a FEV₁ equal to or greater than 80% of predicted normal (FEV₁=forcedexpiratory volume in one second). Exclusion criteria were Diabetesmellitus type 1 or 2, prevalence of human insulin antibodies, history ofhypersensitivity to the study medication or to drugs with similarchemical structures, history or severe or multiple allergies, treatmentwith any other investigational drug in the last 3 months before studyentry, progressive fatal disease, history of drug or alcohol abuse,current drug therapy with other drugs, history significantcardiovascular, respiratory, gastrointestinal, hepatic, renal,neurological, psychiatric and/or hematological disease, ongoingrespiratory tract infection or subjects defined as being smokers withevidence or history of tobacco or nicotine use.

Conduct of the Study

On the morning of the study days, the subjects came to the hospital(fasting, except for water, from midnight onward) at 7:30 a.m. Thesubjects were restricted from excessive physical activities and anintake of alcohol for 24 hours before each treatment day. They wererandomly assigned to one of the three treatment arms. The subjectsreceived a constant intravenous regular human insulin infusion, whichwas kept at 0.15 mU min⁻¹ kg⁻¹ so that serum insulin concentrations wereestablished at 10-15 μU/ml during a period of 2 hours before time point0. This low-dose infusion was continued throughout the test to suppressendogenous insulin secretion. Blood glucose was kept constant at a levelof 90 mg/dl throughout the glucose clamp by a glucose controlledinfusion system (BIOSTATOR™). The glucose clamp algorithm was based onthe actual measured blood glucose concentration and the grade ofvariability in the minutes before to calculate the glucose infusionrates for keeping the blood glucose concentration constant. The insulinapplication (5 U i.v. or 10 U s.c. injection or three deep breathsinhalation per capsule (2 capsules with 50 U each) applied with acommercial inhalation device (Boehringer Ingelheim)) had to be finishedimmediately before time point 0. The duration of the clamp experimentwas 6 hours from time point 0. Glucose infusion rates, blood glucose,serum-insulin and C-peptide were measured.

Bioefficacy and Bioavailability

To determine bioefficacy, the areas under the curve of the glucoseinfusion rates were calculated for the first 3 hours (AUG₀₋₁₈₀ after theadministration and for the overall observation period of six hours afterthe administration (AUC₀₋₃₆₀) and were correlated to the amount ofinsulin applied. To determine bioavailability, the areas under the curveof the insulin concentrations were calculated for the first 3 hours(AUG₀₋₁₈₀ after the administration and for the overall observationperiod of six hours after the administration (AUC₀₋₃₆₀) and correlatedto the amount of insulin applied.

In this clamp study, inhalation of 100 U of TECHNOSPHERE™/Insulin waswell tolerated and was demonstrated to have a substantial blood glucoselowering effect with a relative bioavailability of 25.8% for the firstthree hours as calculated from the achieved serum insulinconcentrations. TECHNOSPHERES™ are microparticles (also referred toherein as microspheres) formed of diketopiperazine that ofself-assembles into an ordered lattice array at particular pHs,typically a low pH. They typically are produced to have a mean diameterbetween about 1 and about 5 μm.

Results

The pharmacokinetic results are illustrated in FIGS. 1 and 2 and inTable 1.

Efficacy Results

Inhalation of 100 U of TECHNOSPHERE™/Insulin (inhalation of 100 U)revealed a peak of insulin concentration after 13 min (intravenous(i.v.) (5U): 5 min, subcutaneous (s.c.) (10 U): 121 min) and a return ofthe insulin levels to baseline after 180 min (i.v.: 60 min, s.c. 360min). Biological action as measured by glucose infusion rate peakedafter 39 min (i.v. 14 min, s.c.: 163 min) and lasted for more than 360min (i.v.: 240 min, s.c.: >360 min). Absolute bioavailability(comparison to i.v. application) was 14.6±5.1% for the first 3 hours and15.5±5.6% for the first 6 hours. Relative bioavailability (comparison tos.c. application) was 25.8±11.7% for the first 3 hours and 16.4±7.9% forthe first 6 hours.

TABLE 1 Pharmacokinetic Parameters Intravenous SubcutaneousAdministration Inhaled Administration Parameter Calculated on GlucoseInfusion Rate T50%* 9 min 13 min 60 min Tmax 14 min 39 min 163 minT-50%** 82 min 240 min 240 min T to baseline 240 min >360 min >360 minParameter Calculated on Insulin Levels T50%* 2 min 2.5 min 27 min Tmax 5min 13 min 121 min T-50%** 6 min 35 min 250 min T to baseline 60 min 180min 360 min *time from baseline to half-maximal values **time frombaseline to half-maximal after passing Tmax

Safety Results

TECHNOSPHERE™/Insulin was shown to be safe in all patients. One patientwas coughing during the inhalation without any further symptoms or signsof deterioration of the breathing system.

Conclusions

Inhalation of 100 U of TECHNOSPHERE™/Insulin was well tolerated and wasdemonstrated to have a substantial blood glucose lowering effect with arelative bioavailability of 25.8% for the first 3 hours as calculatedfrom the achieved serum insulin concentrations.

Summary

In this study, the inhalation of TECHNOSPHERE™/Insulin (the formulationof example 1) was demonstrated in healthy human subjects to have atime-action profile with a rapid peak of insulin concentration (Tmax: 13min) and rapid onset of action (Tmax: 39 min) and a sustained actionover more than 6 hours. The total metabolic effect measured afterinhalation of 100 U of TECHNOSPHERE™/Insulin was larger than aftersubcutaneous injection of 10 U of insulin. The relative bioefficacy ofTECHNOSPHERE™/Insulin was calculated to be 19.0%, while the relativebioavailability was determined to be 25.8% in the first three hours.

The data also show that inhalation of TECHNOSPHERE™/Insulin resulted ina much more rapid onset of action than s.c. insulin injection that wasclose to the onset of action of i.v. insulin injection, while durationof action of TECHNOSPHERE™/Insulin was comparable to that of s.c.insulin injection.

The drug was well tolerated and no serious adverse events were reportedduring the entire trial.

Example 3 Removal of Impurity from Proprietary Peptide

A proprietary peptide containing an impurity was trapped in fumaryldiketopiperazine, forming a peptide/fumaryl diketopiperazineprecipitate. The precipitate was washed with water to remove theimpurity. The peptide is rather unstable and trapping it in fumaryldiketopiperazine markedly improves its stability; both as a dry powderand in aqueous suspension for injection.

Example 4 Stabilized Glucagon Formulations

Formulation

Glucagon was formulated under sterile conditions, into a stabilizedcomplex by precipitation in acidic solution with fumaryldiketopiperazine(3,6bis[N-fumaryl-N-(n-butyl)amino]-2,5-diketopiperazine). The complexwas washed and lyophilized, yielding a sterile dry powder formulation ofdiketopiperazine/glucagon (hereinafter referred to as “TG”) containingfrom 1.2 to 8.2% glucagon by weight, depending upon the formulationparameters desired (allowing physicians to increase dose yet keep thevolume constant). The TG powder was suspended in an appropriate mediasuitable for subcutaneous delivery in a MiniMed 507C infusion pump.

Stability Protocol

Glucagon and TG were suspended in infusion media and incubated at40.degree. C. in a water bath for varying amounts of time up to 150hours.

Glucagon HPLC Analysis

An adaptation of USP method for glucagon analysis was employed. A WatersSymmetry Shield RP8 column (5 μm, 3.9×150 mm) and guard RP8 column (5μm, 3.9×20 mm) were used at a flow rate of 1 mL/min. and a detectionwavelength of 214 nm. The gradient method consisted of mobile phase A:9.8 g NaH₂PO₄ (0.0816 M) and 170 mg L-cysteine (1.4 mM) per liter HPLCgrade water, adjusted pH to 2.6 with phosphoric acid; and B:acetonitrile. Glucagon solutions were diluted as needed with water andinjected. TG samples were prepared by adding 1/10^(th) volume 1 M TrispH 10.0 to sample to solubilize the fumaryl diketopiperazine.

Rat Study Protocol

Sprague Dawley rates 200-250 g were fasted overnight and givensubcutaneous injection of glucagon or TG (0.75 mg/kg) in an appropriatemedia that had been held at 25° C. for 0, 24, or 48 hours. Blood sampleswere taken at −10, −5, 0, 5, 10, 15, 20, 30, 45, and 60 minutes postdose and analyzed for blood glucose (HemCue B-glucose analyzer, HemocueAB, Angelholm Sweden). Mean baseline was determined (pre-dosemeasurements) and was subtracted from the subsequent data and plottedvs. time. This was done to assure that the TG formulation, whichappeared to not degrade significantly, showed appropriatepharmacological activity.

Results

Following 40° C. incubation, HPLC analysis showed an increase inbreakdown products in the glucagon preparation. By contrast, TG has onlyone minor degradation peak (RT=6) which correlated with the slightlyless active oxidative form of glucagon. Glucagon withoutdiketopiperazine (i.e. without TECHNOSPHERES™) had many degradationpeaks, some of which contributed to an enhanced effect and others thatreduced the potency of glucagon.

The TG sterile lyophilized powder was shipped frozen to a hospital,where it was re-suspended in sterile media. The material re-suspendedwell and each vial was continuously infused over a 72 hour period.

Conclusion

Standard preparations of glucagon are not suitable for regulation ofblood glucose by continuous subcutaneous infusion. Administration ofsuch preparations containing variable amounts of the deamidated andhydrolysed forms resulted in highly variable blood glucose levels.Suspensions of TECHNOSPHERES™/glucagon, which is stabilized, does notaggregate and contains clinically irrelevant amounts of breakdownproducts. As such TG can be and has been used as a therapy forhyperinsulinemia, providing consistent, elevated glucose levels whenadministered subcutaneously over time.

Modifications and variations of the present invention will be obvious tothose of skill in the art from the foregoing detailed description. Suchmodifications and variations are intended to come within the scope ofthe following claims.

1. A method for delivering a peptide to a patient in need thereof,comprising administering to said patient a delivery formulation for saidpeptide comprising an effective amount of said peptide complexed with adiketopiperazine derivative, wherein said delivery formulation isprepared by complexing said peptide with microparticles of saiddiketopiperazine derivative by the steps of: a) providing pre-formedmicroparticles of diketopiperazine in a suspension comprising a solvent;b) adding said peptide to said suspension; and c) removing solvent fromsaid suspension; wherein said diketopiperazine derivative has theformula 2,5-diketo-3,6-di(4-X-aminobutyl)piperazine, wherein X isselected from the group consisting of fumaryl, succinyl, maleyl, andglutaryl, and wherein said microparticles release said peptide upondissociation.
 2. The method of claim 1 wherein the composition is in adry powder form administered to the lungs via inhalation.
 3. The methodof claim 1 wherein the patient is a Type II diabetic.
 4. The method ofclaim 3 wherein the composition is administered concurrently with, orless than 20 minutes prior to, the patient eating a meal.
 5. The methodof claim 1 wherein said solvent is an aqueous solvent.
 6. The method ofclaim 1 wherein said solvent is removed by lyophilizing or freezedrying.
 7. The method of claim 1 wherein said peptide is glucagon.
 8. Acomposition for administration of a peptide to a patient, wherein saidcomposition comprises a peptide and a diketopiperazine derivative and isprepared by complexing said peptide with microparticles of saiddiketopiperazine derivative by the steps of: a) providing pre-formedmicroparticles of diketopiperazine in a suspension comprising a solvent;b) adding said peptide to said suspension; and c) removing solvent fromsaid suspension; and wherein said diketopiperazine derivative has theformula 2,5-diketo-3,6-di(4-X-aminobutyl)piperazine, wherein X isselected from the group consisting of fumaryl, succinyl, maleyl, andglutaryl.
 9. The composition of claim 8, wherein said microparticlesrelease said peptide upon dissociation.
 10. The composition of claim 8,wherein the peptide is glucagon.
 11. A composition for theadministration of a peptide to a patient comprising a peptide complexedwith a diketopiperazine.
 12. The composition of claim 11, wherein thepeptide is glucagon.
 13. A method for making a composition comprising apeptide and a diketopiperazine derivative comprising: a) complexing saidpeptide with microparticles of said diketopiperazine derivative by thesteps of: i) providing pre-formed microparticles of saiddiketopiperazine derivative in a suspension comprising a solvent; ii)adding said peptide to said suspension; and iii) removing solvent fromsaid suspension; and wherein said diketopiperazine derivative has theformula 2,5-diketo-3,6-di(4-X-aminobutyl)piperazine, wherein X isselected from the group consisting of fumaryl, succinyl, maleyl, andglutaryl.
 14. The method of claim 13, wherein said microparticlesrelease said peptide upon dissociation.
 15. The method of claim 13,wherein said solvent is an aqueous solvent.
 16. The method of claim 13wherein said solvent is removed by lyophilizing or freeze drying. 17.The method of claim 13 wherein X is fumaryl.
 18. The method of claim 13wherein said peptide is insulin.
 19. The method of claim 13 wherein saidpeptide is glucagon.
 20. The method of claim 1 wherein X is fumaryl. 21.The method of claim 1 wherein said peptide is insulin.
 22. Thecomposition of claim 8 wherein X is fumaryl.
 23. The composition ofclaim 8 wherein said peptide is insulin.